markets · · fool.com
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam's stock has plunged more than 40% this year, but the company's financials look great. Investors have been spooked by a guidance cut and a rival drug's clinical setback.
Alnylam's stock has plunged more than 40% this year, but the company's financials look great. Investors have been spooked by a guidance cut and a rival drug's clinical setback.
- #ALNY